Navigation Links
The Female Health Company Reports Record Profit for Both Fourth Quarter and Fiscal Year 2007


- 4th Qtr. Revenue Increases 17% to $5.2 M

- 4th Qtr. Net Income of $1.2M, incl. $.8M tax benefit, up 2,230%

- FY '07 revenue up 30%, or $4.5 M

- FY '07 net income of $1.6M, including tax benefit, up 1,243%

- FY '07 unit sales increase 32%

CHICAGO, Nov. 26 /PRNewswire-FirstCall/ -- The Female Health Company (Amex: FHC), which manufactures and markets the FC Female Condom(R), today reported its operating results for the quarter and year ended September 30, 2007.

For the three months ended September 30, 2007, net revenues increased 17% to $5.2 million, compared with $4.4 million in the three months ended September 30, 2006. The Company reported net income attributable to common shareholders of $1.2 million, or $0.04 per diluted share, for the fourth quarter of FY2007, versus $.05 million, or $0.00 per diluted share, for the same period last year.

Gross profit increased 34% to $2 million in the most recent quarter, compared with $1.5 million in the fourth quarter of FY2006. Operating income increased 503% to $491,398 in the three months ended September 30, 2007, compared with $81,552 in the corresponding period of the previous fiscal year.

The Company expects significant quarter-to-quarter variations in its operating results, due to the timing of large order receipts, production scheduling, and shipping of products.

For the year ended September 30, 2007, revenues increased 30% to $19.3 million, compared with $14.8 million in fiscal 2006. Gross profit increased 30% to $7.2 million in the year ended September 30, 2007, compared with $5.5 million in fiscal 2006. Operating income rose to $964,900, a 301% improvement from $240,355 in fiscal 2006. In 2007, the Company sold 25.9 million female condoms, an increase of 32% over the 19.6 million units sold in fiscal 2006.

Net income attributable to common shareholders for fiscal 2007 of $1.6 million, or $0.06 per diluted share, represents a 1,243% increase when compared with net income of $120,778 or $0.01 per diluted share, in fiscal 2006. In 2007, the Company was able to recognize a tax benefit for past losses which added $825,000 to net income attributable to common shareholders.

Shareholders' equity at September 30, 2007 totals $7.4 million versus $4.8 million at the end of fiscal year 2006. The Company has no outstanding debt and $1.5 million of unused credit lines.

In January 2007, the Company announced a Stock Repurchase Program under the terms of which up to a million shares of its common stock could be purchased during the subsequent twelve months. Through September 30, 2007, the Company has purchased 173,400 shares for $367,472. The Board has approved the continuation of this program through December 31, 2008.

"We are very pleased to report strong revenue and earnings growth for the quarter and year ended September 30, 2007," noted O.B. Parrish, Chief Executive Officer of The Female Health Company. "The strong performance in the most recent quarter reflects continued growth in global demand for the female condom, including excellent acceptance of our second-generation product. Most importantly, the growth in the use of the female condom reflects increased protection against HIV/AIDS."

As previously announced, the Female Health Company will host an investor conference call at 11:00 a.m. Eastern time, November 26, 2007. Shareholders and other interested parties may participate in the conference call by dialing 888-603-6873 (international participants dial 973-582-2706) and entering the conference code 9473190, a few minutes before 11:00 a.m. Eastern Time on November 26, 2007. A replay call will be available through December 10, 2007 by dialing 877-519-4471 (international callers dial 973-341-3080) and entering the conference code 9473190.

About The Female Health Company

The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC Female Condom(R), which is primarily distributed by public health organizations and donor groups in over 90 developing countries around the world. World-wide, the Female Condom is available in various programs in 108 countries. The Company owns certain worldwide rights to the FC Female Condom(R), including patents that have been issued in the United States, United Kingdom, Japan, France, Italy, Germany, Spain, the European Patent Convention, the People's Republic of China, Canada, South Korea and Australia. FC Female Condom(R) is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy.

"Safe Harbor" statement under the Private Securities Litigation Reform Action of 1995: The statements in this release which are not historical fact are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.

For more information about the Female Health Company visit the Company's web site at and

If you would like to be added to an e-mail alert list, please send an e-mail to

The Female Health Company

Unaudited Condensed Consolidated Balance Sheet

September 30, September 30,

2007 2006

$ $

Cash 799,421 1,827,393

Restricted cash 86,435 237,741

Accounts receivable, net 6,080,153 3,160,801

Inventory 1,372,582 1,011,672

Prepaid and other current assets 399,536 413,532

Total current assets 8,738,127 6,651,139

Other non-current assets 251,536 187,940

Deferred income taxes 825,000

Net property, plant & equipment 1,378,885 606,693

Total assets $11,193,548 $7,445,772

Accounts payable $806,134 $599,023

Accrued expenses 1,555,346 970,439

Preferred dividends payable 53,025 11,210

Total current liabilities 2,414,505 1,580,672

Deferred gain on sale of facilities 1,074,339 1,092,775

Deferred grant income 257,245

Total liabilities 3,746,089 2,673,447

Total stockholders' equity 7,447,459 4,772,325

Total liabilities and stockholders' equity $11,193,548 $7,445,772

The Female Health Company

Unaudited Condensed Consolidated Income Statements

For the 3 Months Ended For the 12 Months Ended

September 30, September 30,

2007 2006 2007 2006

Net revenues $5,174,227 $4,422,103 $19,319,889 $14,824,242

Gross profit 2,030,921 1,513,908 7,156,315 5,489,410

Advertising and promotion 48,854 60,237 179,874 218,500

Selling, general and

administrative 1,438,730 1,276,759 5,802,933 4,819,679

Research and development 51,939 95,360 208,608 210,876

Total operating expenses 1,539,523 1,432,356 6,191,415 5,249,055

Operating income 491,398 81,552 964,900 240,355

Interest, net and

other income 61,796 (11,196) 6,995 (41,671)

Pretax income 429,602 92,748 957,905 282,026

Income tax benefit (825,000) - (825,000) -

Net income 1,254,602 92,748 1,782,905 282,026

Preferred dividends 40,643 40,643 161,248 161,248

Net income attributable

to common stockholders $1,213,959 $52,105 $1,621,657 $120,778

Net income per share- basic $0.05 $0.00 $0.06 $0.01

Weighted average common

shares outstanding

- basic 25,970,280 23,905,630 24,952,440 23,801,167

Net income per

share - diluted $0.04 $0.00 $0.06 $0.01

Weighted average shares

outstanding- diluted 28,145,652 26,494,568 26,398,565 26,494,568

SOURCE The Female Health Company
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
4. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
7. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
8. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
9. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
10. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
11. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
Post Your Comments:
(Date:10/11/2017)... Bay, Florida (PRWEB) , ... October 11, 2017 ... ... and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel ... (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the cell ...
(Date:10/10/2017)... Philadelphia, PA (PRWEB) , ... October 10, 2017 ... ... University City Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. ... accept the award for Excellence in Volunteer Experience from US2020. , US2020’s mission ...
(Date:10/10/2017)... CRUZ, Calif. , Oct. 10, 2017 ... grant from the NIH to develop RealSeq®-SC (Single Cell), ... kit for profiling small RNAs (including microRNAs) from single ... Analysis Program highlights the need to accelerate development of ... "New techniques for measuring ...
(Date:10/9/2017)... 2017  BioTech Holdings announced today identification and ... ProCell stem cell therapy prevents limb loss in ... demonstrated that treatment with ProCell resulted in more ... compared to standard bone marrow stem cell administration.  ... reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
Breaking Biology News(10 mins):